SHENZHEN, CHINA, March 15 /PRNewswire-FirstCall/ - Hard to Treat
Diseases (HTDS; http://www.htdsmedical.com/) is pleased to announce
that the Chilean government approved two of the company's penem
injectables.
Following 18 months of testing and negotiations, Chilean ISP
(Ministry of Health) approved two of HTDS' penem injectables,
Meropenem for Injection (MEINEN) and Imipenem for Injection
(IMINEN). HTDS received the registration certificate for these two
medications from the Chilean ISP and the company prepares to ship
its products to this emerging South American market. Meropenem and
Imipenem See link
http://www.cdc.gov/ncidod/dhqp/ar_lab_imipenem.html are antibiotics
with wide range of efficiency, treating infections in lungs, heart,
blood, bone, stomach, etc., and offer great market value for the
producers and distributors.
HTDS' CEO Terry Yuan said, "We
are happy that we finalized the test stage for these two products
and received the ISP's certificate. The certificate will strengthen
our supply capacity for the market. HTDS - Mellow Hope through our
Chilean agent holds a powerful position on the local injectables
market. Aligning these two facts, we believe that these two
antibiotics will succeed in Chile
and bring solid sales numbers to HTDS. Overall, penem injectables
have great market potential globally, and we continue to seek new
market and distribution opportunities around the world." More on
penem injectables can be found by visiting
www.oxfordjournals.org
The company reminds our shareholders and followers that the
company does not subscribe to the PinkSheets.com Filing Service.
Its IR company web site section "CLIENT SUPPORT" TAB
www.minamargroup.net or this direct link
http://minamarmarketinggroup.helpserve.com/should be reviewed by
its followers for further updates on this and other business
matters. Non-newsworthy events are not press released however
posted on this separate support sites to keep our followers advised
of day-to-day events, and the company corporate web site. For any
matters relating to retail investor queries or to send us the
company directly a message please click on the "INVESTOR SUPPORT"
TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases,
industry updates, and non-weekly activity at the company that may
or may not be news released, please subscribe or opt in mailer at
www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases